Insulet expands credit facility as MarketBeat keeps Hold on Insulet stock

Published on 10/01/2026 at 13:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Insulet stock costs EUR 115.55 on October 1, 2026 after EUR 115.15, plus 0.35 percent. Second-quarter revenue rose 23.5 percent to USD 801.7 million.

Reinraum-Fertigung Insulet – Medizintechnik-Mitarbeiter montieren Insulinpumpen-Pods an Edelstahlbänken — Insulet Reinraum in der Medizintechnik: Mitarbeiter montieren schlauchfreie Insulin-Pods an Edelstahlbänken, ISIN US45784P1012, Illustration mit AI erstellt.

Insulet (ISIN US45784P1012) was trading at EUR 115.55 at Lang & Schwarz on October 1, 2026 at 1:47 p.m. CEST, up 0.35 percent versus the prior close of EUR 115.15. The company expanded its revolving credit commitments to USD 750.0 million in an amendment dated September 21, 2026, according to MarketScreener. The financing change gives Insulet additional liquidity while investors weigh slower expected growth in its U.S. Omnipod business.

Credit capacity reaches USD 750.0 million

The September 21 amendment refinanced USD 475.0 million of term loans and increased revolving commitments by USD 250.0 million. The facility was undrawn at closing, while the interest margin on the new term loans was reduced by 0.25 percentage points, according to MarketScreener. For investors, the amendment matters because it combines refinancing with a larger pool for working capital and general corporate purposes.

Revenue grows as guidance resets

Insulet reported USD 801.7 million of revenue in the second quarter of 2026, a 23.5 percent year-over-year increase, while adjusted earnings per share rose to USD 1.66 from USD 1.17 in the prior-year quarter, according to The Globe and Mail. Adjusted gross margin reached 72.90 percent, up 3.20 percentage points year over year, showing that scale and manufacturing productivity supported profitability despite the guidance reset.

Management lowered full-year 2026 U.S. Omnipod growth guidance to 17.00 percent to 19.00 percent from 20.00 percent to 22.00 percent. At the same time, international Omnipod growth guidance rose to 30.00 percent to 32.00 percent from 26.00 percent to 28.00 percent, according to CNBC. The contrast makes customer retention in the type 2 market the key operating variable for the remainder of 2026.

Hold consensus meets wide target gap

MarketBeat reports a consensus Hold rating, with 13 Buy, 11 Hold and 2 Sell ratings among 26 firms and an average 12-month target of USD 195.40. The target is 49.79 percent above the USD 130.47 primary-exchange quote from September 30, 2026, but the comparison also highlights the gap between analyst expectations and the companys revised U.S. growth outlook.

Insulet stock remains near its yearly low

Insulet was last quoted at USD 130.47 on Nasdaq on September 30, 2026 at 4:00 p.m. ET. Its USD 126.40 to USD 354.88 52-week range and USD 9.0 billion market capitalization show that the stock remains much closer to its yearly low than its yearly high.

The further course of trading is shown by the continuously updated real-time quote of Insulet stock.